Epitomee Medical Ltd · TASE:EPIT
Epitomee Medical — Investor Presentation (October 2026)
29 slides from Epitomee Medical's investor presentation, October 2026
Slide 1: Business Focus & Growth Strategy: US Weight Management Market
Business Focus & Growth Strategy US Weight Management Market Investor Presentation October 2026 1 TASE: EPIT
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) is for informational purposes only and does not constitute or form any part of any offer or solicitation to buy or subscribe for securities of Epitomee Medical Ltd. (the “Company”) and should not be regarded as a recommendation or an opinion on such
Slide 3: Investment Highlights
Investment Highlights Epitomee is leveraging its hydrogel scaffold technology to commercialize an FDA-cleared weight-management medical device and to develop a future drug-delivery pipeline FDA-cleared, non-drug Rx capsule Clinically demonstrated efficacy 1 FDA-cleared, CE-marked and registered with
Slide 4: Experienced Management Team Positioned for US Commercial Entry
Experienced Management Team Positioned for US Commercial Entry Shimon Eckhouse, PhD Dolev Rafaeli, PhD Co-founder, Chairman and largest shareholder Chief Executive Officer Founder of Syneron NASDAQ: ELOS & Lumenis CEO Radiancy Inc; NASDAQ: LMNS, Sofwave Medical TLV: SOFW and others CEO PhotoMedex In
Slide 5: Epitomee Capsule Designed to Meet Rapidly Rising Demand for Weight Management Products
Epitomee® Capsule Designed to Meet Rapidly Rising Demand for Weight Management Products GROWTH DRIVERS Global obesity drug spending This growth is driven by $160 rising obesity rates and advancements in weight $140 $130B management products. $120 $100 $Billion $80 $60 $40 $30B $20 $- Source: IQVIA I
Slide 6: The GLP-1 Weight-Maintenance Gap: An Opportunity for Epitomee
The GLP-1 Weight-Maintenance Gap: An Opportunity for Epitomee® 65% 2/3 1 in 12 of patients without type 2 diabetes of prior weight loss regained within 1 are still taking a GLP- (non-T2D) stop GLP-1s within 12 year of stopping semaglutide2; other 1 at 3 years7 months1 studies show similar regain3,4
Slide 7: Epitomee Targeting US Market of 172 Million Eligible Patients
Epitomee Targeting U.S. Market of 172 Million Eligible Patients Million patients, current state 22M Epitomee® Entry Market SOM: patients aligned with Epitomee® Epitomee® value proposition (seeking up to 10% weight Entry Market loss, maintenance or intolerant to GLP-1) SOM 70M Patients with mild/no c
Slide 8: The Epitomee Capsule
The Epitomee® Capsule » ae ight management capsule
Slide 9: Unique Mechanism of Action Provides a Non-Drug Alternative to GLP-1
The Epitomee® Capsule’s Unique Mechanism of Action Provides a Non-Drug Alternative to GLP-1 1 2 3 4 Ingest Expand Satiate Disintegrate Epitomee® Capsule Hydrogel scaffold Expanded hydrogel Hydrogel scaffold ingested with water expands in stomach provides feeling of disintegrates in the small before
Slide 10: Epitomee Capsule Is FDA-Cleared, CE-Marked and Registered with AMAR
Epitomee® Capsule Is FDA-Cleared, CE-Marked and Registered with AMAR A non-drug, clinically proven capsule that, by expanding in the stomach, helps users feel full, eat less, and stay on track ✓ Rx device for adults with BMI 25-40* ✓ No serious device- related adverse events reported ✓ Integrates se
Slide 11: ELECT Participants Maintained 11.2% Mean Weight Loss Through Week 48
ELECT Participants Maintained 11.2% Mean Weight Loss Through Week 48 Weight loss maintained through Week 48; no serious adverse events reported in the extension 11.3% → 11.2% Mean weight loss at Week 24 and Week 48 in ELECT participants A SELECTED COHORT Not all RESET participants continued: only se
Slide 12: Predictable Results: Know by Week 8 Who Will Benefit
Predictable Results: Know by Week 8 Who Will Benefit In RESET, a patient’s weight loss after 8 weeks on Epitomee® predicted the result at 24 weeks YES: about two in three patients (64.5%) 9.3% average weight loss by week 24 WEEK 8 CHECK Lost at least 2% of body weight? NO: the remaining patients ave
Slide 13: Tolerability Is Epitomee's Edge Over GLP-1 Drugs
Tolerability Is Epitomee®’s Edge Over GLP-1 Drugs GLP-1 drugs (e.g., Wegovy®, Zepbound®, Epitomee® capsule (medical device) Foundayo ) Mechanical: a gel expands in the stomach to create a feeling of Hormonal: a drug absorbed into the bloodstream that acts on How it works fullness; not absorbed into
Slide 14: Additional Epitomee Health Benefits in Peer-Reviewed Literature
Additional Epitomee® Health Benefits in Peer-Reviewed Literature Early Waistline Weight Improved Improvement in Improvements in Safe & response3 reduction2,5 management1-6 Quality of life4 Metabolic cardiometabolic drug-free1-6 syndrome2 risk factors2 1. Ard JD, Ryan DH, O’Neil PM, et al. Efficacy a
Slide 15: US Market Entry Strategy
US Market Entry Strategy TWO CHANNELS Direct-to-Consumer 1 2 B2B Partnerships Telehealth 15
Slide 16: Potential Segments Underserved by Current Weight-Management Options
Potential Segments Underserved by Current Weight-Management Options PATIENTS WHO DISCONTINUED GLP-1 DRUGS Stopped GLP-1 treatment Maintain weight loss after GLP-1 treatment 65% of patients without type 2 diabetes stop GLP-1 drugs within a year; Patients who stop typically regain about two-thirds of
Slide 17: US TeleHealth Go-to-Market Strategy
US TeleHealth Go-to-Market Strategy A streamlined operation driven by targeted digital marketing and telehealth platform 1 2 3 4 Discovery Intake and Prescription Fulfillment Deliver Targeted DTC ads via Meta, Asynchronous telehealth clinical If clinically appropriate, the provider Epitomee Capsule
Slide 18: Sample DTC Ad Creatives
Sample DTC Ad Creatives Anew yach to weight managem INGESTING EXPANDING. SATIATING DISINTEGRATING epit eoitemee ,2;3in. Reduced in waistline in the first 24 weeks’ epitemee A breakthrough in healthy, non-drug weight management. Habererettsen) belaeeattien glasses of water Regular heathy 30 minutes:
Slide 19: US 1st B2B Partnership: ReviveHealth
US 1st B2B Partnership: ReviveHealth What is ReviveHealth? An employer health-benefits and virtual-care platform for US employers, serving 3,000+ organizations and 4M+ members*. A licensed pharmacy owned by ReviveHealth is also the dispensing pharmacy for Epitomee's US direct-to-consumer telehealth
Slide 20: Commercial Rollout: OUS
Commercial Rollout: OUS EXPANSION THROUGH LOCAL DISTRIBUTORS Israel 1 2 Europe Home market 20
Slide 21: Epitomee Targeting Large Opportunity in Israel Home Market
Epitomee Targeting Large Opportunity in Israel Home Market THE OPPORTUNITY GO-TO-MARKET: ISRAEL - THE HOME-BASE MARKET Exclusive Distributor in Israel Almost 60% Epitomee Partnered with Rafa, a pharmaceutical company and distributor, Rx and OTC, manufacturing, logistics and marketing. of Israelis ar
Slide 22: Capturing the European Market Opportunity
Capturing the European Market Opportunity $8.1B $22.5B 12.1% CAGR European GLP-1 market, all indications incl. Projected European GLP-1 market by 2033 Projected growth through 2033* T2D (2025)* (incl. T2D)* OUR GO-TO-MARKET STRATEGY 1 Market Approach 2 Distribution Partners 3 Operations Localized st
Slide 23: Manufacturing Scale-Up
Manufacturing Scale-Up Scaling production to support commercial growth
Slide 24: State-of-the-Art Production Process
State-of-the-Art Production Process 1 Raw material 2 Thin film coating 3 Robotic assembly 24
Slide 25: Estimated Manufacturing Capacity: Scale-Up Plan
Estimated Manufacturing Capacity: Scale-Up Plan Annual capacity, thousand boxes 1000 ~48M Capsules 900 800 50k units ~2.7M Capsules. At the end of 2026, we 700 Thousands boxes estimate a yearly 600 Manufacturing capacity of 168k units ~9.4M capsules ~24M Capsules ~24M Capsules 500 400 864 ~15M Capsu
Slide 26: Next Steps
Next Steps ACCELERATING GROWTH Growth roadmap 26
Slide 27: On Track for Achievable Growth in Fast-Growing Weight Management Market
On Track for Achievable Growth in Fast-Growing Weight Management Market Global Expansion: ROW & EU US B2B Partnerships Distribution agreements signed; product shipped to First B2B agreement signed with ReviveHealth Germany, Spain and Chile (employer weight program) Next: Expand partnerships and geog
Slide 28: Why Epitomee, Why Now
Why Epitomee, Why Now FDA-cleared product Proven clinical results ✓ FDA-cleared (Sept 2024), CE-marked and registered with ✓ RESET: ×2.5 more patients lost ≥10% (27% vs. 11%)1; selected AMAR; non-drug Rx capsule for adults with BMI 25-40 RESET participants who completed 24 weeks of Epitomee® treatme
Slide 29: Thank you
epitemee Thank you
Epitomee Medical — Investor Presentation (October 2026) on 6ix